Illumina launched the Billion Cell Atlas to train AI on one billion single cells. AstraZeneca, Merck and Lilly are founding ...

The Billion Cell Atlas, backed by Eli Lilly, MSD and AstraZeneca, maps mechanisms to support informed drug discovery and ...

Illumina unveiled the Billion Cell Atlas, a large‑scale genetic perturbation dataset built with pharma partners to advance AI‑powered drug discovery, target validation, and disease biology.

Cancer immunity and immunotherapy research increasingly recognizes that chronic inflammation is a major driver of tumorigenesis, yet the complex and dynamic ...

The Atlas will enable the validation of genetic targets and training of AI models at unprecedented scale SAN DIEGO, Jan. 13, ...

AI Impact explores why AI security has outgrown human oversight, plus pricing gains, health care insight and key AI moves in ...

Explore the groundbreaking AI genomics platform, Inference, launched by Variant Bio to enhance drug discovery using genetic ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...

How AI, robotics, and modular design are transforming single-cell and spatial biology into scalable, precision-driven engines of discovery.

Frost & Sullivan is pleased to announce that BostonGene has been recognized for 2025 Global Technology Innovation Leadership in the ...

The field of cancer immunotherapy has achieved remarkable progress, introducing strategies such as immune checkpoint inhibitors and adoptive cell therapies ...

Stress during pregnancy such as gut changes or a trigger of the immune system can impact the brain health of the foetus, ...